ArticleFrontiers in oncology2026
Primary breast diffuse large B-cell lymphoma mimicking breast carcinoma: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary breast lymphoma (PBL) is an exceedingly rare extranodal malignancy that frequently mimics breast carcinoma on clinical and radiological examination, posing a significant diagnostic challenge. Case presentation: We report a case of a 39-year-old Chinese woman who presented with two palpable right breast masses. Imaging revealed suspicious lesions classified as Breast Imaging-Reporting and Data System 4A, prompting surgical excision and biopsy. Histopathological examination and immunohistochemical (IHC) analysis confirmed a diagnosis of diffuse large B-cell lymphoma, germinal center B-cell subtype. Staging by 18F-fluorodeoxyglucose positron emission tomography/computed tomography established disease as Ann Arbor stage IE, asymptomatic (stage IEA) with an International Prognostic Index score of 0. The patient was initiated on R-CHOP chemoimmunotherapy and demonstrated a favorable response after three cycles, with no evidence of recurrence. Conclusion: This case highlights the importance of histopathological and IHC evaluation in differentiating PBL from breast carcinoma. Early and accurate diagnosis is essential to guide appropriate treatment and optimize patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.